Cargando…
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
Two different 6-month GnRH agonist depot formulations approved for palliative treatment of advanced and metastatic prostate cancer in the United States – leuprolide acetate 45 mg and triptorelin pamoate 22.5 mg – provide patients with efficacy and safety comparable to those of existing 1-, 3-, and 4...
Autores principales: | Crawford, E David, Phillips, Jason M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154964/ https://www.ncbi.nlm.nih.gov/pubmed/21847353 http://dx.doi.org/10.2147/CMR.S12700 |
Ejemplares similares
-
Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding
por: Flanagan, Colleen A., et al.
Publicado: (2017) -
Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023) -
Effects of Different Exposure Days to Gonadotropin-Releasing Hormone Agonist (GnRH-a) on Live Birth Rates in the Depot GnRH-a Protocol: A Retrospective Analysis of 7007 Cycles
por: Song, Jianyuan, et al.
Publicado: (2021) -
Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022) -
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer
por: Gründker, Carsten, et al.
Publicado: (2003)